Abp-788.mp4 -

Below is a draft guide based on the clinical profile of the ARX788 therapy, which the video likely covers.

ARX788 is a site-specific ADC designed to target and HER2-low cancers. Unlike traditional therapies, it uses a unique non-natural amino acid technology to link a potent toxin directly to an antibody, ensuring the "payload" is delivered specifically to cancer cells while sparing healthy tissue. 1. Clinical Applications & Efficacy ABP-788.mp4

The "guide" in the video likely explains the : Below is a draft guide based on the

: A potent tubulin inhibitor that kills the cancer cell once the antibody binds to the HER2 receptor and is internalized. : In the ACE-Breast-02 trial , ARX788 significantly

: Uses a highly stable oxime bond to prevent the premature release of the toxin into the bloodstream, which reduces systemic side effects.

: In the ACE-Breast-02 trial , ARX788 significantly improved progression-free survival (PFS) to 11.3 months compared to 8.2 months for standard treatments.